ReviewJournal of chemical biology2014
Resistance to antifungals that target CYP51.
Review in Journal of chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 191 citations in OpenAlex.
- Pichia kudriavzevii (Candida krusei): A systematic review to inform the World Health Organisation priority list of fungal pathogens.Medical mycology · 2024Pooled it
- Chemical Profiling and Antimicrobial Activity of the Leaf Essential Oil ofInternational journal of molecular sciences · 2026Article
- Computational Discovery of Novel CYP51 Inhibitors for Antifungal Therapy Against Aspergillus fumigatus.Probiotics and antimicrobial proteins · 2026Article
- Candicidal Effect of a Nanoemulsion Based on the Essential Oil of the Medicinal PlantPharmaceuticals (Basel, Switzerland) · 2026Article
- Microwave-assisted single-step synthesis of cyclic and acyclic β-aminosulfones and evaluation of their antifungal activity targeting CYP51.RSC medicinal chemistry · 2026Article
- Nanotechnology-driven strategies to overcome azole resistance inFrontiers in plant science · 2026Review
- Molecular mechanisms drivingFrontiers in molecular biosciences · 2026Review
- Proteomic and Phosphoproteomic Landscapes of Azole Resistance in Aspergillus fumigatus Biofilm Exposed to Voriconazole.Mycopathologia · 2025Article
- First Isolation of a Multi-azole-Resistant Aspergillus fumigatus cyp51A TRMycopathologia · 2025Article
- Antidermatophytic activity of Curcuma longa against Trichophyton spp.: compound identification and molecular docking to lanosterol 14α-demethylase.BMC complementary medicine and therapies · 2025Article
- Review
- Review
- Profiling difenoconazole and flusilazole resistance, fitness penalty and phenotypic stability in Venturia inaequalis.Scientific reports · 2025Article
- Activity of Azole and Non-Azole Substances AgainstInternational journal of molecular sciences · 2025Article
- Two-dimensional QSAR-driven virtual screening for potential therapeutics againstFrontiers in chemistry · 2025Article
- From crops to clinic: the impact of dual azole use on antifungal resistance inFrontiers in microbiology · 2025Review
- Molecular Identification ofInfection and drug resistance · 2025Article
- Article
- Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.Biomedicines · 2024Review
- Azole Resistance in Veterinary Clinical Aspergillus fumigatus Isolates in the Netherlands.Mycopathologia · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal diseases are an increasing global burden. Fungi are now recognised to kill more people annually than malaria, whilst in agriculture, fungi threaten crop yields and food security. Azole resistance, mediated by several mechanisms including point mutations in the target enzyme (CYP51), is increasing through selection pressure as a result of widespread use of triazole fungicides in agriculture and triazole antifungal drugs in the clinic. Mutations similar to those seen in clinical isolates as long ago as the 1990s in Candida albicans and later in Aspergillus fumigatus have been identified in agriculturally important fungal species and also wider combinations of point mutations. Recently, evidence that mutations originate in the field and now appear in clinical infections has been suggested. This situation is likely to increase in prevalence as triazole fungicide use continues to rise. Here, we review the progress made in understanding azole resistance found amongst clinically and agriculturally important fungal species focussing on resistance mechanisms associated with CYP51. Biochemical characterisation of wild-type and mutant CYP51 enzymes through ligand binding studies and azole IC50 determinations is an important tool for understanding azole susceptibility and can be used in conjunction with microbiological methods (MIC50 values), molecular biological studies (site-directed mutagenesis) and protein modelling studies to inform future antifungal development with increased specificity for the target enzyme over the host homologue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.